Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Immuneglory.com
WARNING LETTER
•Immuneglory.com

Immuneglory.com – FDA Warning Letter

Record Details

The FDA and FTC issued a Warning Letter to Arenvy Laboratories, Inc. following a review of their website, www.immuneglory.com, concerning the marketing of ImmuneGlory products. The FDA determined that ImmuneGlory products are unapproved new drugs, violating sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, as they are not generally recognized as safe and effective for their labeled uses, which include treating and preventing herpes and cold sores. The products are also misbranded under section 502(j) because they are dangerous to health when used as labeled, potentially causing consumers to delay appropriate medical treatment. Furthermore, the labeling fails to provide adequate directions for use for conditions requiring professional supervision, leading to misbranding under section 502(f)(1). The introduction of these unapproved and misbranded drugs into interstate commerce violates sections 301(a) and (d). Specifically, orally administered products promoted for cold sores are considered new drugs and misbranded per 21 CFR § 310.537(b) and section 502. The firm must promptly correct these violations, notify the FDA within fifteen working days of corrective actions, and address distributed products. The FTC also requires substantiation of claims with competent scientific evidence, warning of potential legal action including injunctions and consumer repayment.

Company
Immuneglory.com
Product type
Drugs
Office
San Francisco District Office
People
  • Barbara J. Cassens (Director )
  • Deborah M. Autor (Former FDA Deputy Commissioner)
  • Mary K. Eagle
View Company Profile

ID · 3eadc3b6-00f1-4e28-8aad-5cf5483b68f4

Violation Codes10
21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 35221 U.S.C. 352(f)(1)21 U.S.C. 352(j)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 CFR 201.521 CFR 201.100(c)(2)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Immuneglory.com
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.